Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Wednesday, July 29, 2026
Raj Abhushan Bhandar Vs. The Assistant Registrar of Trade Marks
Monday, July 27, 2026
BioPharma Inc. Vs. Deputy Controller of Patents
Delhi High Court Remands Array BioPharma Cancer Combination Patent Application for Fresh Reconsideration
Array BioPharma Inc. Vs. Deputy Controller of Patents and Designs:23.07.2026:C.A.(COMM.IPD-PAT) 37/2023:2026:DHC:5856:Hon'ble Mr. Justice Tushar Rao Gedela
Factual and Procedural Background
Array BioPharma Inc. filed Indian Patent Application No. 450/DELNP/2015 on January 19, 2015, titled "PHARMACEUTICAL COMBINATION COMPRISING A BRAF INHIBITOR AN EGFR INHIBITOR AND OPTIONALLY A PI3K ALPHA INHIBITOR", tracing priority to a US application filed on August 7, 2012. Following the issuance of the First Examination Report and multiple rounds of hearings, the Deputy Controller of Patents and Designs passed an order on June 30, 2023 under Section 15 of the Patents Act, 1970, refusing the grant of patent. The refusal was based on grounds of lack of inventive step under Section 2(1)(ja), non-patentability under Section 3(d), non-patentability under Section 3(i), and non-compliance with Section 10(4) and Section 10(5). Aggrieved by this rejection, the applicant filed an appeal under Section 117A of the Patents Act before the High Court of Delhi.
Dispute before Court
The central dispute was whether the claimed pharmaceutical combination comprising a B-Raf inhibitor (Encorafenib), an EGFR inhibitor (Cetuximab or Erlotinib), and optionally a PI3K-alpha inhibitor (Alpelisib) lacked an inventive step over prior art citations D1 to D4. Additionally, the Court had to determine whether the subject application fell under the statutory bar of Section 3(d) as a non-patentable form or derivative of a known substance without enhanced efficacy, and whether the phrase "for simultaneous, separate or sequential administration" transformed a product combination claim into a non-patentable method of treatment under Section 3(i) of the Patents Act, 1970.
Reasoning of Judge
The Court observed that none of the cited prior art documents D1 to D4 disclosed or suggested the specific dual or triple combination of Encorafenib, Cetuximab/Erlotinib, and Alpelisib, nor did they provide any motivation for a person skilled in the art to combine these precise active pharmaceutical agents. The Controller failed to conduct a proper analysis of inventive step or identify any technical problem solved over the closest prior art. Regarding Section 3(d), the Court held that the provision applies when an invention is a new form of a known substance, and the Controller failed to identify any base "known compound" of which the claimed combination was alleged to be a derivative. On Section 3(i), the Court affirmed that Claim 1 was explicitly structured as a product claim for a pharmaceutical combination rather than a treatment method, protocol, or dosing schedule. The description of administration modes served merely as a functional descriptor of the product, and working examples in the specification demonstrating practical utility do not alter the product nature of the claims.
Decision
The High Court of Delhi set aside the impugned refusal order dated June 30, 2023, and remanded the patent application back to the Controller of Patents and Designs for a de novo reconsideration on its merits. The Court directed the Controller to dispose of the matter within six months from the date of receipt of the order after providing a fair opportunity of hearing to the appellant.
One Important legal principle held in the case
A pharmaceutical combination product claim is not converted into a non-patentable method of treatment under Section 3(i) of the Patents Act, 1970 merely because the claims or complete specification describe administration schedules or include working examples demonstrating practical clinical feasibility.
[Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation ]
=====
Analytical Legal Article on Patentability of Pharmaceutical Combination Claims
Introduction:
The legal framework governing pharmaceutical patents in India strikes a delicate balance between encouraging genuine technical innovation and preventing the unwarranted extension of patent monopolies. Central to this balance are statutory provisions under the Patents Act, 1970 that exclude certain subject matters from patentability, particularly those relating to mere derivatives of known substances and methods of medical treatment. A recurrent issue in patent prosecution concerns whether claims directed to pharmaceutical combinations containing known active ingredients constitute patentable product inventions or barred therapeutic regimens. This judgment of the High Court of Delhi provides critical clarity on the threshold of inventive step, the scope of Section 3(d), and the boundaries of Section 3(i) exclusions when adjudicating pharmaceutical combination patent applications.
Factual and Procedural Background:
The subject patent application, numbered 450/DELNP/2015 and titled "PHARMACEUTICAL COMBINATION COMPRISING A BRAF INHIBITOR AN EGFR INHIBITOR AND OPTIONALLY A PI3K ALPHA INHIBITOR", originated from a priority US application filed on August 7, 2012. An international PCT application was filed on August 5, 2013, published internationally on February 13, 2014, and subsequently entered the Indian national phase on January 19, 2015. The application was published under Section 11A of the Patents Act, 1970 on June 26, 2015, and a formal request for examination was filed on August 1, 2016.
The Patent Office issued a First Examination Report on August 24, 2018, to which a detailed response was submitted on February 6, 2019. Following hearing notices, adjournments, and formal hearings held under Section 15 of the Act, along with written submissions and clinical data filed on record, the Deputy Controller of Patents and Designs issued an order on June 30, 2023. The Controller refused the patent application on the grounds of lack of inventive step under Section 2(1)(ja), non-patentability under Sections 3(d) and 3(i), and lack of clarity and definitive scope under Sections 10(4)(c) and 10(5) of the Patents Act, 1970. The applicant then preferred a statutory appeal under Section 117A before the High Court of Delhi challenging the refusal order.
Dispute Before the Court
The main dispute before the Court revolved around whether the Patent Office was justified in refusing the patent application for a pharmaceutical combination designed for the treatment of proliferative diseases such as colorectal cancer. The primary legal issue was whether the claimed combination lacked an inventive step under Section 2(1)(ja) in light of four prior art documents cited by the Patent Office. A key factual controversy pertained to whether a person skilled in the art, reading the prior art documents, would have had the motivation or reasonable expectation of success to combine the specific active pharmaceutical agents selected by the applicant.
Another essential issue was whether the subject application fell within the non-patentability bar of Section 3(d) of the Act. The Patent Office contended that the combination comprised known compounds without showing enhanced efficacy over known prior art. The applicant countered that Section 3(d) is inapplicable to a combination of distinct, independent active pharmaceutical agents having different chemical structures and mechanisms of action.
Finally, a major point of contention was the applicability of Section 3(i) of the Act, which prohibits patents for processes of medicinal or therapeutic treatment of human beings. The Patent Office argued that because the claims referenced simultaneous, separate, or sequential administration and the specification outlined clinical trial dosing protocols, the claimed invention was essentially a method of medical treatment. The applicant maintained that the claims were strictly product claims defining a pharmaceutical combination entity, and that administration descriptors and clinical examples merely demonstrated industrial applicability and practical workability.
Reasoning and Analysis of the Court
In analyzing the objection regarding lack of inventive step under Section 2(1)(ja) of the Act, the Court conducted a comprehensive, document-by-document evaluation of the four cited prior arts. Prior art D1 disclosed B-Raf inhibitors generally and taught combinations with MEK inhibitors, but provided no teaching or disclosure regarding combinations with EGFR or PI3K-alpha inhibitors. Prior art D2 focused on diagnostic and prognostic methods for detecting mutations and mentioned EGFR signaling inhibitors generally in combination with unspecified RAF inhibitors, without disclosing the specific B-Raf inhibitor Encorafenib. Prior art D3 disclosed combinations of dabrafenib with an unspecified PI3K inhibitor, but contained no reference to EGFR inhibitors such as Erlotinib or Cetuximab. Prior art D4 was directed to novel PI3K inhibitors as chemical entities and discussed in vitro models involving EGFR, but failed to disclose the specific combination claimed.
The Court concluded that none of the cited prior art documents, whether viewed individually or collectively, disclosed or suggested the specific dual combination of Encorafenib with Erlotinib or Cetuximab, or the triple combination incorporating Alpelisib. The Court observed that the Controller failed to identify the closest prior art document, articulate the specific technical problem solved by the invention, or explain how a person skilled in the art would be motivated to select and combine these specific active ingredients from a vast landscape of known compounds. Furthermore, the Court highlighted that the clinical data in the specification demonstrated significant technical advancement and synergistic therapeutic effects, including tumor regression, which had not been properly evaluated by the Controller.
Addressing the objection under Section 3(d) of the Act, the Court noted that Section 3(d) applies to the mere discovery of a new form of a known substance or derivatives unless they differ significantly in efficacy. The Court emphasized that for Section 3(d) to be invoked, the decision-maker must explicitly identify the base known compound. Relying upon the principle affirmed in Topotarget UK Ltd. vs. Controller General of Patents & Designs [IPDPTA/50/2023], the Court reiterated that a combination of two or more independent active pharmaceutical agents, each possessing a distinct chemical identity and therapeutic mechanism, cannot be treated as derivatives of each other under Section 3(d). The Controller's failure to identify any specific known compound rendered the Section 3(d) finding legally unsustainable.
On the challenge under Section 3(i) of the Act, the Court examined the structural language of Claim 1. Section 3(i) prohibits processes for therapeutic treatment, but does not exclude pharmaceutical products or combinations. The Court held that the phrase "for simultaneous, separate or sequential administration" functions merely as a descriptor defining the range of ways the constituent active ingredients in the combination product can be delivered, without transforming the product claim into a process or method step.
To reinforce this legal standard, the Court referred to established precedents including Societe Des Produits Nestle SA vs. Controller of Patents & Designs [CA (COMM).IPD-PAT) 22/2022] and Medilabo RFP Ink Inc. vs. Controller of Patents [CA (COMM).IPD-PAT) 16/2024], which established that using expressions relating to treatment or administration to define a composition does not attract Section 3(i). Furthermore, drawing upon the principles laid down in Bayer Pharma Aktiengesellschaft vs. The Controller of Patents and Design [2024:DHC:2395], the Court clarified the fundamental legal distinction between claim scope and working examples. Working examples and clinical protocols set out in a patent specification serve to demonstrate the practical feasibility and workability of an invention under Section 10(4) of the Act, but do not dictate or expand the legal boundaries of the claim itself. Since Claim 1 was drafted as a product claim for a pharmaceutical combination, Section 3(i) was completely inapplicable.
The Court also briefly evaluated principles from related jurisprudence including Ranbaxy Laboratories Ltd. vs. The Controller of Patents & Designs [OA/15/2011/PT/MUM], Ajantha Pharma Ltd. vs. Allergan Inc. & Ors. [Order No. 173/2013], Biomoneta Research Pvt. Ltd. v. Controller General of Patents & Designs [2023/DHC/001816], Zydus Lifesciences Ltd. v. ER Squibb & Sons LLC [2026:DHC:178-DB], and Novartis AG v. Union of India [(2013) 6 SCC 1]. The Court found that the Controller's rejection under Sections 10(4)(c) and 10(5) was entirely devoid of reasoning, making a complete re-examination necessary.
Final Decision of the Court
The Court set aside the impugned order dated June 30, 2023 passed by the Deputy Controller of Patents and Designs under Section 15 of the Patents Act, 1970. The matter was remanded back to the Patent Office for a de novo reconsideration of the patent application on its merits. The Court directed the Controller to afford the applicant a fair hearing and to dispose of the patent application within six months from the date of receipt of the judicial order, while clarifying that the fresh determination must be made independently without being influenced by the observations made in the judgment.
Point of Law Settled
This decision clarifies and reinforces two important principles in Indian patent law. First, it settles that a product claim directed to a pharmaceutical combination entity cannot be recharacterized as a non-patentable process or method of treatment under Section 3(i) of the Patents Act, 1970 simply because the claim describes administration modes or because the complete specification details clinical trial protocols and dosing schedules. Second, it affirms that when rejecting an application under Section 3(d) or Section 2(1)(ja), the Patent Office must specifically identify the base known compound and clearly articulate the technical problem and motivation that would lead a person skilled in the art to combine specific active pharmaceutical agents, rather than relying on generalized mosaic references to prior art.
Title of the Case: Array BioPharma Inc. vs. Deputy Controller of Patents and Designs
Date of Judgment: 23.07.2026
Case Number: C.A.(COMM.IPD-PAT) 37/2023
Neutral Citation: 2026:DHC:5856
Name of Court: High Court of Delhi at New Delhi
Name of Hon'ble Judge: Hon'ble Mr. Justice Tushar Rao Gedela
Written By:Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation .
Headnote of the Judgment:
Array BioPharma Inc. v. Deputy Controller of Patents and Designs, High Court of Delhi, C.A.(COMM.IPD-PAT) 37/2023, Neutral Citation 2026:DHC:5856. The appellant appealed against an order of the Deputy Controller refusing patent application 450/DELNP/2015 for a pharmaceutical combination of a B-Raf inhibitor, an EGFR inhibitor, and optionally a PI3K-alpha inhibitor under Sections 2(1)(ja), 3(d), and 3(i) of the Patents Act, 1970. The High Court found that prior art documents D1 to D4 did not teach or suggest the claimed combination. The Court held Section 3(d) inapplicable as no base known compound was identified, and ruled that Section 3(i) does not bar combination product claims merely because administration modes or clinical examples are described. The High Court set aside the refusal order and remanded the matter for fresh de novo consideration within six months.
Suggested SEO Tags:
Delhi High Court, Patent Law India, Patents Act 1970, Section 3i Patents Act, Section 3d Patents Act, Section 21ja Patents Act, Pharmaceutical Combination Patents, Inventive Step Patent Law, Encorafenib Patent, B Raf Inhibitor, EGFR Inhibitor, PI3K Alpha Inhibitor, Cancer Drug Patent, Patent Office Remand Order, Method of Treatment Exclusion, Working Examples Patent Claims, Patent Efficacy Section 3d, Combination Therapy Patents, Indian Patent Jurisprudence, IP Litigation Delhi High Court, Controller of Patents Refusal, Patent Application Remand, Pharmaceutical Patent Prosecution, High Court Patent Appeal, Section 117A Patents Act, AdvocateAjayAmitabhSuman, IPAdjutor.
Suggested SEO Titles:
Delhi High Court Remands Array BioPharma Cancer Combination Patent Application for Fresh Hearing
Understanding Section 3(i) of Patents Act: Why Combination Products Are Not Methods of Treatment
Delhi High Court Clarifies Patentability of Pharmaceutical Combinations under Indian Patent Law
Array BioPharma Patent Appeal: Delhi HC Overturns Refusal of BRAF and EGFR Inhibitor Claims
Inventive Step and Prior Art Analysis in Pharmaceutical Patent Applications: Delhi HC Ruling
Demystifying Section 3(d) and 3(i) Objections in Indian Patent Law: Lessons from Array BioPharma
Working Examples vs Claim Scope: Delhi High Court Analysis on Patentability of Cancer Drug Combinations
Delhi High Court Sets Aside Patent Office Refusal for Multi Target Cancer Therapy Patent
Legal Insights on Pharmaceutical Combination Claims and Section 3(i) Exclusion in India
Array BioPharma v Deputy Controller of Patents: Analysis of Delhi High Court Remand Order
Friday, July 24, 2026
ADS Spirits Pvt. Ltd. Vs. The Registrar of Trade Marks
Sri. Vishal Vrushabhanaath Samaje Vs. The State of Karnataka
ANI Media Pvt. Ltd. Vs. Open AI OpCo LLC
Delhi High Court Refuses Interim Injunction Against OpenAI in ANI's Copyright Suit Over Use of News Content for Training ChatGPT
ANI Media Pvt. Ltd. Vs. Open AI OpCo LLC:24.07.2026: CS(COMM) 1028/2024:2026:DHC:5900: Hon'ble Judge: Justice Amit Bansal
Factual and Procedural Background
ANI Media Pvt. Ltd., a news agency, filed a suit against Open AI OpCo LLC, the company behind ChatGPT, alleging that Open AI had, without licence, collected and stored ANI's news articles and other literary works to train its large language models, and that ChatGPT generated responses reproducing ANI's content. ANI sought an interim injunction restraining Open AI from using, storing or reproducing its copyrighted works. Several intervenors, including news publisher bodies, music industry associations, and organisations supporting the AI industry, were permitted to join the proceedings, and the Court also appointed amici curiae to assist on the technical and legal questions involved.
Dispute before Court
The Court framed four issues for consideration. First, whether Indian courts had jurisdiction to try the suit given that Open AI's servers are located outside India. Second, whether Open AI's use of ANI's copyrighted material to generate ChatGPT's responses to users amounted to infringement. Third, whether the mere storage of ANI's data for training ChatGPT amounted to infringement. Fourth, whether such storage and use, even if otherwise infringing, was protected as "fair dealing" under Section 52 of the Copyright Act, 1957. ANI argued that Open AI's storage, tokenisation and reproduction of its articles violated its exclusive rights, while Open AI contended that the training process was transformative, akin to how a person learns from reading, and fell within the statutory defence of private or personal use, including research.
Reasoning of Judge
The Court held that it had territorial jurisdiction since Open AI carries on commercial activity, including subscription collection, within Delhi. On the output claim, the Court found that ANI's examples of alleged copying were generated after the training had concluded and did not establish that ChatGPT memorises or substantially reproduces ANI's articles. On the storage and fair use issues, the Court held that Section 52(1)(a) does not exclude commercial use, and that "research" under the provision must be read liberally, including machine-based research such as training an LLM. The Court found the training process transformative in purpose and character, held that ANI had not shown any actual loss of market share or revenue, and noted that LLMs like ChatGPT serve substantial public interest by aiding education, research and access to information.
Decision
The Court held that Open AI's storage of ANI's works for training ChatGPT falls within the fair dealing exception under Section 52(1)(a) of the Copyright Act and does not amount to infringement, and that ANI had not made out a case that ChatGPT's outputs substantially reproduce its works. Holding that ANI failed to establish a prima facie case, and that the balance of convenience and irreparable injury favoured Open AI and the public at large, the Court dismissed I.A. 45300/2024, ANI's application for interim injunction. The Court clarified that these are prima facie observations for the purpose of the interim application only and will not bind the final decision in the suit.
One Important Legal Principle Held in the Case
The use of copyrighted literary works to train large language models can, on a prima facie basis, qualify as "private or personal use, including research" under Section 52(1)(a) of the Copyright Act, 1957, and the commercial nature of such use does not by itself take it outside the protection of fair dealing.
[Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation ]
=====
ANI v Open AI: Delhi High Court Declines to Injunct ChatGPT's Training on News Content, Applies Fair Dealing to Artificial Intelligence
ANI Vs Open AI case:Fair Dealing Meets Artificial Intelligence
Introduction
The rapid growth of generative artificial intelligence has raised a pressing legal question across the world, whether feeding copyrighted material into a machine learning system amounts to copyright infringement. The Delhi High Court has now weighed in on this question in a dispute between ANI Media Pvt. Ltd., one of India's prominent news agencies, and Open AI, the company behind ChatGPT. ANI accused Open AI of using its news articles without permission to train ChatGPT and of generating responses that reproduced its content. Open AI defended its practice as a transformative and research oriented activity protected under the fair dealing provisions of Indian copyright law. In a detailed judgment running into more than a hundred pages, the Court examined how large language models work, how Indian copyright law applies to their training, and whether an interim injunction should be granted while the underlying suit is pending trial. The judgment is significant not only for the news and publishing industry but for the entire artificial intelligence ecosystem operating in or serving users in India.
Factual and Procedural Background
ANI is engaged in gathering, producing and distributing news content, which it licenses to subscribers including media houses and digital platforms. It claimed that Open AI, without obtaining any licence, scraped and stored its articles as part of the raw data used to train the large language models that power ChatGPT, and that ChatGPT's responses to user queries at times closely mirrored its reports. ANI filed a commercial suit seeking a permanent injunction and damages, along with an interim application asking the Court to restrain Open AI from continuing to store, use or reproduce its works during the pendency of the suit. Open AI resisted the application, arguing that its servers and training operations are located outside India, that ANI's material forms an infinitesimally small part of a vast training corpus drawn from the internet, and that the entire process is protected as fair dealing under the Copyright Act. During the proceedings, several parties were allowed to intervene, including bodies representing digital news publishers and the music industry supporting ANI, and organisations representing the broadband and artificial intelligence industry supporting Open AI. The Court also had the benefit of assistance from two amici curiae on the technical workings of large language models and the applicable legal principles.
Dispute Before the Court
The Court identified four core questions that needed to be answered before deciding whether to grant an interim injunction. The first was a threshold question of jurisdiction, since Open AI's servers where the actual training takes place are located in the United States, the Court had to decide whether an Indian court could still entertain a copyright claim relating to that training activity. The second question was whether the answers that ChatGPT generates for its users, if they resemble ANI's news reports, amount to infringement of ANI's copyright. The third was whether the very act of collecting and storing ANI's articles as training data, independent of what ChatGPT later generates, itself amounts to infringement. The fourth, and perhaps the most consequential question, was whether such storage and use, even if it would otherwise infringe copyright, is protected by the fair dealing exception available for private or personal use, including research, under the Copyright Act. In simple terms, ANI's case was that its hard earned journalistic work was being taken without payment or permission and turned into a commercial product that competes with its own business, while Open AI's case was that training an AI model on publicly available text is no different from a student reading widely to learn, and that the law specifically protects such research oriented use.
Reasoning and Analysis of the Court
On jurisdiction, the Court held that since Open AI conducts commercial activity accessible to and monetised from users located in Delhi, including subscription payments, the Court could exercise jurisdiction over the dispute even though the actual training servers are situated abroad. The Court reasoned that the effects of the allegedly infringing activity are felt within its jurisdiction and that this was sufficient at the interim stage.
On the question of whether ChatGPT's outputs infringe ANI's copyright, the Court examined the instances of alleged copying placed on record by ANI and found that these had been generated after Open AI's training process on the relevant data had already concluded. The Court held that isolated post training examples could not establish that ChatGPT actually memorises and reproduces ANI's articles as a general practice, and that in any event the responses shown did not amount to a substantial reproduction of ANI's original expression, since news reporting largely conveys factual events which enjoy thinner copyright protection than works of greater creative content. The Court distinguished several foreign precedents relied upon by ANI, including cases involving verbatim extracts of news articles and cases involving musical works, on the ground that those situations involved either actual verbatim copying or subject matter with a much higher degree of original expression than typical news reporting.
The heart of the judgment lies in its treatment of the storage and fair use questions, which the Court examined together. Open AI took shelter under Section 52(1)(a)(i) of the Copyright Act, which exempts fair dealing for the purpose of private or personal use, including research. ANI argued that this defence could not apply because Open AI's use was commercial, because the underlying copy of the work had to be a lawfully obtained copy, and because training an AI model is not really research in the sense contemplated by the statute. The Court rejected the argument that commercial use automatically falls outside fair dealing, noting that wherever the legislature intended to restrict a Section 52 exception to non-commercial use, it said so expressly, as seen in other clauses of the same section, and that this restriction is conspicuously absent from Section 52(1)(a). The Court also drew support from the Canadian Supreme Court's decision in CCH Canadian Ltd v Law Society of Upper Canada, which held that research must be given a large and liberal meaning and is not confined to non-commercial contexts. The Court further reasoned that the term research, as used in the Copyright Act, is broad enough to include the process by which a machine learning system is trained to recognise patterns in language, since such training is fundamentally an exercise in extracting information and patterns rather than republishing the original text as such.
The Court then applied what it described as a fairness test, considering whether Open AI's use was limited to training its models, whether it caused economic harm to ANI by substituting for its own products in the market, and whether the activity served the larger public interest. Drawing upon recent American decisions concerning the use of copyrighted books to train large language models, the Court accepted that the purpose and character of training an LLM is highly transformative, since the resulting model does not seek to replicate or supplant the original works but instead learns from them to generate new and different kinds of output, capable of translation, summarisation, drafting assistance and a wide range of other tasks quite different from simply reading a news report. The Court noted that ANI had not placed any concrete evidence of lost subscription revenue or market share attributable to Open AI's activities, and therefore could not show that the use displaced ANI's own commercial position. On public interest, the Court observed that large language models contribute meaningfully to education, research, accessibility and the dissemination of knowledge, and that these considerations weigh in favour of treating the training activity as a fair dealing.
Having found that both the purpose test and the fairness test were satisfied, the Court concluded that Open AI's storage of ANI's works for training purposes falls within the protection of Section 52(1)(a) of the Copyright Act. On the question of balance of convenience, the Court weighed ANI's claim, which it noted was capable of being compensated in monetary terms if the suit ultimately succeeds, against the practical consequences of an injunction that would require Open AI to identify and delete specific training data, which could disrupt its operations and would also affect the wider public that relies on ChatGPT for a variety of purposes.
Final Decision of the Court
The Court held, on a prima facie basis, that Open AI's storage of ANI's works for training the large language models underlying ChatGPT is protected under Section 52(1)(a) of the Copyright Act and does not amount to infringement. It further held that ANI had not established that ChatGPT's outputs are a substantial reproduction of its news articles or that any memorisation and regurgitation of its content had taken place. Concluding that ANI had failed to make out a prima facie case, and that the balance of convenience and the risk of irreparable injury both favoured Open AI and the public at large, the Court dismissed ANI's application for an interim injunction. The Court was careful to clarify that its observations were made only for the purpose of deciding the interim application and would have no bearing on the final outcome of the suit, which remains to be decided after trial.
Point of Law Settled
The judgment clarifies, at least at the interim stage, that the use of copyrighted literary works, including news content, to train large language models can fall within the fair dealing exception for private or personal use, including research, under Section 52(1)(a) of the Copyright Act, 1957. It settles that commercial motive alone does not disqualify a party from claiming this defence, since the statute expressly restricts other specific exceptions to non-commercial use but does not do so for Section 52(1)(a). It also underlines that a copyright holder seeking to resist such a defence on grounds of economic harm must produce concrete evidence of market substitution or lost revenue, rather than relying on general apprehension. The decision is likely to significantly influence how Indian courts approach similar disputes involving artificial intelligence companies and copyright owners, and will be closely watched as the broader suit proceeds to trial.
Title of the Case: ANI Media Pvt. Ltd. v. Open AI OpCo LLC
Date of Judgment: 24.07.2026
Case Number: CS(COMM) 1028/2024,
Neutral Citation: 2026:DHC:5900
Name of Court: High Court of Delhi at New Delhi
Name of Hon'ble Judge: Justice Amit Bansal
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation.
Headnote of the Judgment
In ANI Media Pvt. Ltd. v. Open AI OpCo LLC, decided on 24th July 2026, the High Court of Delhi considered ANI's application for an interim injunction restraining Open AI from using and storing its news content to train ChatGPT. The Court held that it had jurisdiction over the dispute, that ANI had not shown substantial reproduction of its works in ChatGPT's outputs, and that Open AI's storage of ANI's articles for training purposes fell within the fair dealing exception for private or personal use, including research, under Section 52(1)(a) of the Copyright Act, 1957, since commercial use does not automatically exclude this defence and the process is transformative and serves public interest. Finding no prima facie case, and holding that the balance of convenience favoured Open AI, the Court dismissed the interim injunction application, clarifying that its findings would not bind the final trial.
Suggested SEO Tags
ANI v Open AI, Delhi High Court judgment, ChatGPT copyright case India, artificial intelligence copyright law, Copyright Act 1957 fair dealing, Section 52 Copyright Act, large language model training data, AI copyright infringement India, news copyright AI training, fair use artificial intelligence, generative AI copyright dispute, ChatGPT news articles case, transformative use copyright India, copyright infringement LLM, interim injunction copyright, ANI Media copyright suit, OpenAI India lawsuit, Justice Amit Bansal judgment, AI training data copyright, research exception copyright law, copyright law technology India, news agency AI dispute, commercial use fair dealing, Delhi High Court IP judgment, copyright and machine learning, AdvocateAjayAmitabhSuman, IPAdjutor
Suggested SEO Titles
Delhi High Court Denies Injunction Against ChatGPT in ANI Copyright Suit
ANI v Open AI: How Indian Courts View AI Training and Copyright Law
Fair Dealing Meets Artificial Intelligence: Analysis of the ANI v Open AI Judgment
Can Training ChatGPT on News Articles Amount to Copyright Infringement? Delhi HC Answers
Delhi High Court on Section 52 Fair Dealing and Large Language Model Training
ANI Media Loses Round One Against OpenAI in Landmark Copyright Battle
Explained: Delhi High Court's Reasoning in the ANI v Open AI Copyright Case
Copyright Law and Generative AI: Lessons from the ANI v Open AI Judgment
Interim Injunction Denied: Delhi High Court Backs Fair Use Defence for AI Training
ANI v Open AI Judgment Explained: Jurisdiction, Fair Dealing and Public Interest
Vishal Prafulsingh Solanke Vs. Controller of Patent and Designs
Bombay High Court Rules No Intra-Court Commercial Appeal Lies Against Single Judge Order Passed Under Section 117A Of Patents Act
Vishal Prafulsingh Solanke Vs. Controller of Patent and Designs:: 09/03/2026:Commercial Appeal (L) No. 13430 of 2025 in Commercial Miscellaneous Petition No. 110 of 2025:2026:BHC-OS:7027-DB:Mrs. Justice Bharati Dangre and Hon'ble Mrs. Justice Manjusha Deshpande
Factual and Procedural Background
The appellants filed patent application number 879/MUM/2015 on 17/03/2015 for an invention titled Thread Type Tamper Evident Security Seal
Dispute before Court
The primary issue before the Division Bench was whether an intra-court appeal under Section 13(1-A) of the Commercial Courts Act, 2015 is maintainable against a judgment or order of a Single Judge of the High Court delivered while exercising appellate jurisdiction under Section 117A of the Patents Act, 1970, or whether such an appeal is barred under Section 100A of the Code of Civil Procedure, 1908
Reasoning of Judge
The Division Bench observed that the Single Judge heard the matter in exercise of statutory appellate jurisdiction under Section 117A of the Patents Act, 1970, and delivered a final judgment determining the rights of the parties
Decision
The High Court held that the commercial appeal filed under Section 13(1-A) of the Commercial Courts Act, 2015 is not maintainable in view of the statutory prohibition contained in Section 100A of the Code of Civil Procedure, 1908, and accordingly dismissed the appeal
One Important legal principle held in the case
An intra-court appeal before a Division Bench under Section 13 of the Commercial Courts Act, 2015 is barred by Section 100A of the Code of Civil Procedure, 1908, when the decision of the Single Judge has been rendered in exercise of statutory appellate jurisdiction under Section 117A of the Patents Act, 1970
[Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation ]
=====
Controller of Patent is having trapping of civil court
Introduction:
The interplay between intellectual property statutes, special commercial legislation, and general procedural law often gives rise to critical procedural questions regarding appellate remedies. Following the abolishment of the Intellectual Property Appellate Board, appeals against decisions of the Controller of Patents were routed directly to the High Courts under Section 117A of the Patents Act, 1970
Factual and Procedural Background:
The dispute originated when the applicants submitted Patent Application number 879/MUM/2015 on 17/03/2015 before the Indian Patent Office seeking protection for an invention titled Thread Type Tamper Evident Security Seal
Seeking relief against the refusal order, the applicants approached the High Court on its original side by filing Commercial Miscellaneous Petition (L) number 25369 of 2023 under Section 117A of the Patents Act, 1970
Dispute Before the Court
The core question that required adjudication by the Court was whether a commercial appeal under Section 13(1-A) of the Commercial Courts Act, 2015 lies before a Division Bench against a judgment delivered by a Single Judge in a statutory appeal under Section 117A of the Patents Act, 1970
The appellants argued that the Single Judge exercised original jurisdiction while entertaining the petition against the decision of the Controller, meaning the resulting judgment was an original decree appealable under Section 13(1-A) of the Commercial Courts Act, 2015
On the other hand, the respondents and amicus curiae contended that the proceeding before the Single Judge was an exercise of statutory appellate jurisdiction under Section 117A of the Patents Act, 1970
Reasoning and Analysis of the Court
The Court engaged in an exhaustive analysis of the statutory framework and relevant legal principles
In examining Section 100A of the Code of Civil Procedure, 1908, the Court stressed that the overarching legislative object of introducing Section 100A was to eliminate multiple tiers of appeals and ensure early finality in legal disputes
Addressing the contention that Section 100A CPC only applies to orders of traditional civil courts, the Court held that the Controller of Patents under Section 77 of the Patents Act, 1970 is invested with significant statutory powers of a civil court, including powers to examine witnesses on oath, order discovery and production of documents, receive evidence on affidavits, and award costs executable as a civil court decree
Final Decision of the Court
The High Court concluded that the Single Judge had decided the matter in exercise of appellate jurisdiction under Section 117A of the Patents Act, 1970
Point of Law Settled
This judgment settles an important procedural principle regarding the jurisdiction of Commercial Appellate Divisions in patent disputes
Title of the Case: Vishal Prafulsingh Solanke and Anr. v. Controller of Patent and Designs and Ors.
Date of Judgment: 09/03/2026
Case Number: Commercial Appeal (L) No. 13430 of 2025 in Commercial Miscellaneous Petition No. 110 of 2025
Neutral Citation: 2026:BHC-OS:7027-DB
Name of Court: High Court of Judicature at Bombay (Ordinary Original Civil Jurisdiction)
Name of Hon'ble Judge: Hon'ble Mrs. Justice Bharati Dangre and Hon'ble Mrs. Justice Manjusha Deshpande
Written By:Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation .
Headnote of the Judgment:
High Court of Judicature at Bombay; Commercial Appeal (L) No. 13430 of 2025; Vishal Prafulsingh Solanke and Anr. v. Controller of Patent and Designs and Ors.; Neutral Citation: 2026:BHC-OS:7027-DB; Judgment Dated 09/03/2026
Suggested SEO Tags:
Patents Act 1970, Section 117A Patents Act, Section 13 Commercial Courts Act, Section 100A CPC, Intra Court Appeal Maintainability, Bombay High Court Judgment, Patent Appeals India, Controller of Patents, Patent Application Refusal, Commercial Division High Court, Commercial Appellate Division, Intellectual Property Law India, Trappings of Civil Court, Quasi Judicial Authority Patents, Patent Litigation India, Pre Grant Opposition Patent, Second Appeal Bar CPC, Letters Patent Appeal Patent, Bombay High Court Patent Ruling, Section 77 Patents Act, Commercial Dispute IP, IP Laws India, Intellectual Property Appellate Jurisdiction, Patent Refusal Appeal, AdvocateAjayAmitabhSuman, IPAdjutor
Suggested SEO Titles:
Maintainability Of Intra Court Appeal Under Section 13 Commercial Courts Act Against Section 117A Patent Judgment
Bombay High Court Rules No Second Appeal Lies Against Single Judge Order Under Patents Act 1970
Bar Of Section 100A CPC On Patent Appeals Explained By Bombay High Court
Is Intra Court Commercial Appeal Maintainable Against Patent Appeal Orders? Bombay High Court Answers
Controller Of Patents As Quasi Judicial Authority: Section 100A CPC Bar Applies To Patent Appeals
Scope Of Section 13 Commercial Courts Act In Patent Dispute Appeals
Bombay High Court Decision On Maintainability Of Commercial Appeals In Patent Cases
Interplay Between Section 117A Patents Act And Section 100A Code Of Civil Procedure
No Letters Patent Or Intra Court Appeal From Single Judge Orders Under Patents Act
Legal Analysis Of Bombay High Court Ruling In Vishal Prafulsingh Solanke v Controller Of Patents
Blog Archive
-
►
2008
(3)
- ► 12/28 - 01/04 (3)
-
►
2009
(7)
- ► 03/08 - 03/15 (1)
- ► 03/22 - 03/29 (2)
- ► 09/13 - 09/20 (1)
- ► 12/20 - 12/27 (3)
-
►
2012
(31)
- ► 09/16 - 09/23 (31)
-
►
2013
(47)
- ► 05/12 - 05/19 (7)
- ► 08/04 - 08/11 (9)
- ► 08/11 - 08/18 (11)
- ► 08/18 - 08/25 (5)
- ► 08/25 - 09/01 (2)
- ► 09/01 - 09/08 (6)
- ► 09/08 - 09/15 (1)
- ► 10/06 - 10/13 (2)
- ► 12/22 - 12/29 (2)
- ► 12/29 - 01/05 (2)
-
►
2014
(1)
- ► 01/12 - 01/19 (1)
-
►
2015
(2)
- ► 03/01 - 03/08 (2)
-
►
2016
(27)
- ► 10/09 - 10/16 (23)
- ► 10/16 - 10/23 (1)
- ► 11/13 - 11/20 (2)
- ► 11/27 - 12/04 (1)
-
►
2017
(49)
- ► 04/23 - 04/30 (16)
- ► 04/30 - 05/07 (1)
- ► 05/07 - 05/14 (3)
- ► 05/14 - 05/21 (2)
- ► 05/21 - 05/28 (3)
- ► 05/28 - 06/04 (1)
- ► 06/11 - 06/18 (1)
- ► 06/25 - 07/02 (1)
- ► 07/30 - 08/06 (1)
- ► 08/06 - 08/13 (3)
- ► 08/13 - 08/20 (1)
- ► 08/20 - 08/27 (1)
- ► 09/03 - 09/10 (2)
- ► 09/24 - 10/01 (3)
- ► 10/29 - 11/05 (1)
- ► 11/12 - 11/19 (2)
- ► 11/26 - 12/03 (1)
- ► 12/10 - 12/17 (6)
-
►
2018
(76)
- ► 01/14 - 01/21 (2)
- ► 01/28 - 02/04 (3)
- ► 02/18 - 02/25 (1)
- ► 03/11 - 03/18 (2)
- ► 03/25 - 04/01 (1)
- ► 04/01 - 04/08 (4)
- ► 04/08 - 04/15 (2)
- ► 04/29 - 05/06 (2)
- ► 05/06 - 05/13 (3)
- ► 05/13 - 05/20 (33)
- ► 05/20 - 05/27 (4)
- ► 06/03 - 06/10 (1)
- ► 07/08 - 07/15 (1)
- ► 07/22 - 07/29 (1)
- ► 08/05 - 08/12 (4)
- ► 08/12 - 08/19 (1)
- ► 08/19 - 08/26 (1)
- ► 08/26 - 09/02 (2)
- ► 09/09 - 09/16 (1)
- ► 09/16 - 09/23 (1)
- ► 10/07 - 10/14 (1)
- ► 10/14 - 10/21 (1)
- ► 11/04 - 11/11 (1)
- ► 12/23 - 12/30 (3)
-
►
2019
(18)
- ► 01/20 - 01/27 (1)
- ► 01/27 - 02/03 (1)
- ► 02/03 - 02/10 (1)
- ► 02/10 - 02/17 (1)
- ► 03/03 - 03/10 (2)
- ► 03/31 - 04/07 (1)
- ► 04/07 - 04/14 (1)
- ► 04/14 - 04/21 (1)
- ► 06/02 - 06/09 (1)
- ► 06/09 - 06/16 (1)
- ► 06/30 - 07/07 (1)
- ► 08/04 - 08/11 (2)
- ► 09/01 - 09/08 (1)
- ► 09/08 - 09/15 (1)
- ► 09/22 - 09/29 (1)
- ► 12/22 - 12/29 (1)
-
►
2020
(6)
- ► 02/23 - 03/01 (2)
- ► 03/22 - 03/29 (1)
- ► 04/12 - 04/19 (1)
- ► 09/27 - 10/04 (1)
- ► 10/18 - 10/25 (1)
-
►
2022
(166)
- ► 06/12 - 06/19 (11)
- ► 06/19 - 06/26 (12)
- ► 06/26 - 07/03 (6)
- ► 07/03 - 07/10 (8)
- ► 07/10 - 07/17 (13)
- ► 07/17 - 07/24 (6)
- ► 07/24 - 07/31 (6)
- ► 07/31 - 08/07 (8)
- ► 08/07 - 08/14 (5)
- ► 08/14 - 08/21 (7)
- ► 08/21 - 08/28 (18)
- ► 08/28 - 09/04 (10)
- ► 09/04 - 09/11 (11)
- ► 09/11 - 09/18 (10)
- ► 09/18 - 09/25 (5)
- ► 09/25 - 10/02 (2)
- ► 10/02 - 10/09 (3)
- ► 10/09 - 10/16 (3)
- ► 10/16 - 10/23 (2)
- ► 10/23 - 10/30 (3)
- ► 10/30 - 11/06 (1)
- ► 11/06 - 11/13 (10)
- ► 11/13 - 11/20 (6)
-
►
2023
(190)
- ► 02/26 - 03/05 (1)
- ► 03/05 - 03/12 (3)
- ► 03/12 - 03/19 (1)
- ► 03/19 - 03/26 (2)
- ► 04/02 - 04/09 (3)
- ► 04/09 - 04/16 (1)
- ► 04/16 - 04/23 (1)
- ► 04/30 - 05/07 (1)
- ► 06/25 - 07/02 (2)
- ► 07/02 - 07/09 (5)
- ► 07/09 - 07/16 (2)
- ► 07/16 - 07/23 (13)
- ► 07/23 - 07/30 (9)
- ► 07/30 - 08/06 (4)
- ► 08/06 - 08/13 (12)
- ► 08/13 - 08/20 (1)
- ► 08/20 - 08/27 (12)
- ► 09/03 - 09/10 (9)
- ► 09/10 - 09/17 (7)
- ► 09/17 - 09/24 (10)
- ► 09/24 - 10/01 (7)
- ► 10/01 - 10/08 (8)
- ► 10/08 - 10/15 (6)
- ► 10/15 - 10/22 (9)
- ► 10/22 - 10/29 (4)
- ► 10/29 - 11/05 (6)
- ► 11/05 - 11/12 (6)
- ► 11/12 - 11/19 (5)
- ► 11/19 - 11/26 (3)
- ► 11/26 - 12/03 (4)
- ► 12/03 - 12/10 (8)
- ► 12/10 - 12/17 (5)
- ► 12/17 - 12/24 (10)
- ► 12/24 - 12/31 (5)
- ► 12/31 - 01/07 (5)
-
►
2024
(361)
- ► 01/07 - 01/14 (4)
- ► 01/14 - 01/21 (4)
- ► 01/21 - 01/28 (7)
- ► 01/28 - 02/04 (3)
- ► 02/04 - 02/11 (16)
- ► 02/11 - 02/18 (7)
- ► 02/18 - 02/25 (7)
- ► 02/25 - 03/03 (7)
- ► 03/03 - 03/10 (12)
- ► 03/10 - 03/17 (14)
- ► 03/17 - 03/24 (7)
- ► 03/24 - 03/31 (11)
- ► 03/31 - 04/07 (2)
- ► 04/07 - 04/14 (4)
- ► 05/12 - 05/19 (31)
- ► 05/19 - 05/26 (6)
- ► 05/26 - 06/02 (12)
- ► 06/02 - 06/09 (21)
- ► 06/09 - 06/16 (16)
- ► 06/16 - 06/23 (12)
- ► 06/23 - 06/30 (8)
- ► 06/30 - 07/07 (6)
- ► 07/07 - 07/14 (13)
- ► 07/14 - 07/21 (12)
- ► 07/21 - 07/28 (8)
- ► 07/28 - 08/04 (21)
- ► 08/04 - 08/11 (10)
- ► 08/11 - 08/18 (13)
- ► 08/18 - 08/25 (16)
- ► 08/25 - 09/01 (8)
- ► 09/01 - 09/08 (6)
- ► 09/08 - 09/15 (6)
- ► 09/15 - 09/22 (6)
- ► 09/22 - 09/29 (13)
- ► 09/29 - 10/06 (7)
- ► 10/06 - 10/13 (4)
- ► 12/29 - 01/05 (1)
-
►
2025
(1119)
- ► 01/05 - 01/12 (17)
- ► 01/12 - 01/19 (17)
- ► 01/19 - 01/26 (16)
- ► 01/26 - 02/02 (14)
- ► 02/02 - 02/09 (8)
- ► 02/09 - 02/16 (28)
- ► 02/16 - 02/23 (40)
- ► 02/23 - 03/02 (40)
- ► 03/02 - 03/09 (42)
- ► 03/09 - 03/16 (35)
- ► 03/16 - 03/23 (33)
- ► 03/23 - 03/30 (20)
- ► 03/30 - 04/06 (28)
- ► 04/06 - 04/13 (10)
- ► 04/13 - 04/20 (20)
- ► 04/20 - 04/27 (12)
- ► 04/27 - 05/04 (36)
- ► 05/04 - 05/11 (30)
- ► 05/11 - 05/18 (40)
- ► 05/18 - 05/25 (27)
- ► 05/25 - 06/01 (17)
- ► 06/01 - 06/08 (15)
- ► 06/08 - 06/15 (13)
- ► 06/15 - 06/22 (19)
- ► 06/22 - 06/29 (32)
- ► 06/29 - 07/06 (33)
- ► 07/06 - 07/13 (24)
- ► 07/13 - 07/20 (31)
- ► 07/20 - 07/27 (19)
- ► 07/27 - 08/03 (9)
- ► 08/03 - 08/10 (12)
- ► 08/10 - 08/17 (27)
- ► 08/17 - 08/24 (24)
- ► 08/24 - 08/31 (29)
- ► 08/31 - 09/07 (29)
- ► 09/07 - 09/14 (21)
- ► 09/14 - 09/21 (11)
- ► 09/21 - 09/28 (18)
- ► 09/28 - 10/05 (3)
- ► 10/05 - 10/12 (5)
- ► 10/12 - 10/19 (15)
- ► 10/19 - 10/26 (10)
- ► 10/26 - 11/02 (11)
- ► 11/02 - 11/09 (8)
- ► 11/09 - 11/16 (13)
- ► 11/16 - 11/23 (14)
- ► 11/23 - 11/30 (24)
- ► 11/30 - 12/07 (24)
- ► 12/07 - 12/14 (30)
- ► 12/14 - 12/21 (10)
- ► 12/21 - 12/28 (39)
- ► 12/28 - 01/04 (17)
-
▼
2026
(447)
- ► 01/04 - 01/11 (25)
- ► 01/11 - 01/18 (17)
- ► 01/18 - 01/25 (12)
- ► 01/25 - 02/01 (17)
- ► 02/01 - 02/08 (12)
- ► 02/08 - 02/15 (6)
- ► 02/15 - 02/22 (12)
- ► 02/22 - 03/01 (14)
- ► 03/01 - 03/08 (13)
- ► 03/15 - 03/22 (12)
- ► 03/22 - 03/29 (7)
- ► 03/29 - 04/05 (6)
- ► 04/12 - 04/19 (29)
- ► 04/19 - 04/26 (27)
- ► 04/26 - 05/03 (20)
- ► 05/03 - 05/10 (12)
- ► 05/10 - 05/17 (11)
- ► 05/17 - 05/24 (14)
- ► 05/24 - 05/31 (10)
- ► 05/31 - 06/07 (24)
- ► 06/07 - 06/14 (17)
- ► 06/14 - 06/21 (64)
- ► 06/21 - 06/28 (11)
- ► 06/28 - 07/05 (1)
- ► 07/05 - 07/12 (24)
- ► 07/12 - 07/19 (11)
- ► 07/19 - 07/26 (10)
-
▼
07/26 - 08/02
(9)
- BioPharma Inc. Vs. Deputy Controller of Patents
- Raj Abhushan Bhandar Vs. The Assistant Registrar o...
- Vaishnani Vipul Dalsukhbhai Vs State of Gujarat
- JK Engineering Private Limited Vs ANE Industries P...
- Parle Products Pvt Ltd Vs The Registrar of Trade M...
- Godfrey Phillips India Limited Vs I T C Limited
- V-Guard Industries Limited Vs Kangaro Industries
- TV Today Network Vs Saurashtra Aaj Tak
- Raj Abhushan Bhandar Vs The Assistant Registrar of...
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
A Party is not allowed to argue a case, what is not pleaded. Introduction: This case revolves around a fundamental principle of civil proce...
-
Introduction In the dynamic realm of pharmaceutical innovation, where intellectual property rights safeguard groundbreaking discoveries, th...
My Blog List
-
प्रश्नोत्तर - ===== वकील: हे वासुदेव! एक शंका आज भी मेरे मन को उद्वेलित करती है। आपने धर्म की स्थापना के लिए महाभारत का युद्ध कराया। युद्ध के उपरान्त कर्णपुत्र वृषकेतु पा...1 week ago
-
IPL:Spice In, Nationality Out - I was sitting in my office. It was a hot afternoon. The fan was running slowly and making strange sounds like an old typewriter. Files were lying on my d...1 year ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री